RxDoctor Payments Data

Faith Ornelas, NP

Psychiatric/Mental Health · Crown Point, INNPI 1023004140

Payments from drug & device makers

$2,838in general payments, 2019–2025

Across 104 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547
  • Alkermes, Inc.$402
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$311
  • Tris Pharma Inc$306
  • Teva Pharmaceuticals USA, Inc.$210
  • Otsuka America Pharmaceutical, Inc.$187
  • plus $876 from 15 others

What the payments were for

  • Food & beverage$2,838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,838 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$26,676
Medicare patients
79
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl28$58,671
CaplytaLumateperone Tosylate16$29,434
VyvanseLisdexamfetamine Dimesylate26$12,507
Oxcarbazepine83$4,855
Atomoxetine Hcl17$4,681
Lamotrigine ErLamotrigine18$4,357
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$4,333
Aripiprazole32$3,633
Duloxetine Hcl120$2,188
Buspirone Hcl97$2,139
Ziprasidone Hcl34$1,860
Hydroxyzine Hcl86$1,777
Olanzapine56$1,444
Sertraline Hcl115$1,265
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$547$58,67128 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$311$29,43416 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$12$12,50726 claims
Almatica Pharma LLCSertraline Hcl$63$1,265115 claims
Teva Pharmaceuticals USA, Inc.Loxapine$210$41017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →